Pay in 4 interest-free payments of $6.40 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
A 17% Reduction in Overall Cancer Risk A landmark study published in JAMA Oncology (Dai H et al., August 2025), drawing on data from 14 health systems encompassing approximately 20 million patients, found that adults with obesity who were prescribed GLP-1 receptor agonists had a 17% lower risk of developing cancer compared to carefully matched non-users
Published in the Journal of Clinical Investigation Insight , the research found that inconsistent use of GLP-1 drugs may reduce their effectiveness when patients resume treatment
30 , 477492.e476 (2019)
For this reason, DSIP is most often studied in the context of sleep architecture, stress regulation, and neuroendocrine balance rather than as a pure sleep-onset agent
